S&P Biotech ETF (CURE) – Global X ETFs Australia
Australia
Search

CURE

S&P Biotech ETF

Invest in CURE Request Research
Overview Performance Holdings & Characteristics Research Documents Announcements FAQs

Reasons to Consider CURE

High Growth Potential

Genomic sequencing and genetic medicines & therapeutics are helping transform health care in key areas with growing demand, including drug development, precision medicine, and more.

Risk Controls

Limit company-specific risks, such as risk of testing failures or higher than anticipated development costs, by using an equal weighting across many biotechnology companies.

Targeted Exposure

CURE provides global exposure to emerging areas within the Health Care sector, at the intersection of science and technology.

Product Information As of 2 May 2024

Inception Date 8 Nov 2018
Management Costs (% p.a.) 0.45
Currency Hedged No
Domicile Australia
Legal Form Managed Investment Scheme
SMSF Eligible Yes

NAV Information As of 2 May 2024

NAV/Unit (A$) 46.22470000
Currency (NAV) AUD
Shares Outstanding 844,012
AUM (A$) 39,014,170.56
NAV History File View

Product Summary

The Global X S&P Biotech ETF (CURE) seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.

Product Objective

The Global X S&P Biotech ETF (CURE) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the S&P Biotechnology Select Industry Index.

Trading Details

Ticker CURE
Bloomberg Code CURE AU Equity
ISIN AU0000028110
Trading Hours 10:00AM – 4:00PM

Management & Administration

Issuer Global X Management (AUS) Limited
Custodian The Hongkong and Shanghai Banking Corporation Limited, Sydney Branch
Registrar Computershare Investor Services Pty Limited

Benchmark Information

Benchmark S&P Biotechnology Select Industry Index
Provider S&P Indices
Ticker SPSIBIN

Distributions As of 28 Mar 2024

12-Month Yield 0.00%
12-Month Franking Level 0.00%
Distribution Frequency Annually
Distribution History View

Performance Table As of 2 May 2024

Total Return (Fund) Total Return (Benchmark) Tracking Difference Tracking Error
1 Month -2.81% -2.73% -0.08% 0.36%
3 Months 0.23% 0.33% -0.11% 0.38%
1 Year 12.80% 13.58% -0.78% 0.55%
3 Year p.a. -8.65% -8.37% -0.28% 1.00%
5 Year p.a. 2.00% 2.42% -0.41% 0.86%
10 Year p.a. -- -- -- --
Since Inception p.a. 2.67% 3.09% -0.42% 0.84%

Top Holdings As of 3 May 2024

Full Holdings (.xlsx)
Net Assets (%) Name SEDOL Market Price (Local) Shares Held Market Value (A$)
1.80 ALPINE IMMUNE SC BYX38M1 64.60 7,088 700,505
1.39 IMMUNITYBIO INC BNSP0B8 8.97 39,590 543,291
1.32 MODERNA INC BGSXTS3 125.59 2,689 516,655
1.32 REVOLUTION MEDIC BL71K91 39.19 8,591 515,079
1.26 BLUEPRINT MEDICI BWY52P3 107.00 3,002 491,416
1.20 CRINETICS PHARMA BDD19F8 46.78 6,552 468,909
1.17 PTC THERAPEUTICS B17VCN9 33.62 8,892 457,353
1.15 UNITED THERAPEUT 2430412 258.13 1,140 450,192
1.15 VIKING THERAPEUT BQQG1V1 75.76 3,860 447,386
1.14 ROIVANT SCIENCES BMW4NZ9 11.24 25,942 446,092
1.14 NATERA INC BYQRG48 93.72 3,111 446,054
1.14 SAREPTA THERAPEU B8DPDT7 130.63 2,228 445,259
1.13 GERON CORP 2370381 3.95 72,849 440,226
1.12 CEREVEL THERAPEU BMVMJ12 42.59 6,717 437,661
1.10 AMGEN INC 2023607 278.39 1,012 431,012
1.10 EXACT SCIENCES 2719951 60.54 4,615 427,434
1.09 NEUROCRINE BIOSC 2623911 139.83 1,990 425,704
1.09 ALNYLAM PHARMACE B00FWN1 150.31 1,849 425,187
1.08 EXELIXIS INC 2576941 22.12 12,475 422,163
1.06 IONIS PHARMACEUT BDJ0LS6 43.09 6,298 415,178
1.06 CYTOKINETICS INC BBBSBJ5 64.34 4,214 414,792
1.06 TG THERAPEUTICS B828K63 16.42 16,512 414,789
1.06 RHYTHM PHARMACEU BF2YWG4 40.98 6,606 414,157
1.06 DYNE THERAPEUTIC BN15WD1 26.00 10,405 413,876
1.06 BIOMARIN PHARMAC 2437071 83.80 3,224 413,327
1.05 REGENERON PHARM 2730190 937.61 286 410,245
1.05 VERTEX PHARM 2931034 400.16 670 410,169
1.04 BRIDGEBIO PHARMA BK1KWG8 27.74 9,561 405,756
1.04 BIOGEN INC 2455965 213.51 1,241 405,364
1.04 HALOZYME THERAPE 2975098 39.82 6,639 404,444
1.01 KRYSTAL BIOTECH BD6JX35 160.23 1,612 395,151
1.00 INSMED INC 2614487 25.66 9,959 390,955
1.00 IRONWOOD PHARMAC B3MZ6K5 8.30 30,751 390,474
0.99 IDEAYA BIOSCIENC BK0VHF6 41.49 6,081 385,987
0.99 IMMUNOVANT INC BJRFSB7 28.78 8,743 384,951
0.98 VERICEL CORP BSBMN89 47.88 5,207 381,414
0.98 ABBVIE INC B92SR70 160.81 1,549 381,083
0.97 DYNAVAX TECHNOLO BRJZSK0 11.72 21,086 378,074
0.97 SYNDAX PHARMACEU BN7Q7R7 21.86 11,277 377,136
0.96 VAXCYTE INC BKPVGH6 64.55 3,812 376,447
0.96 INCYTE CORP 2471950 53.09 4,616 374,915
0.94 GILEAD SCIENCES 2369174 65.33 3,688 368,603
0.94 NOVAVAX INC BJDQXG4 4.71 50,838 366,323
0.93 NUVALENT INC-A BMVBZD3 72.49 3,283 364,086
0.93 ULTRAGENYX PHARM BJ62Z18 43.20 5,483 362,374
0.93 CELLDEX THERAPEU BJLV8T9 40.86 5,783 361,498
0.93 TWIST BIOSCIENCE BGKG6G7 32.01 7,375 361,162
0.92 SPRINGWORKS THER BGMGM89 43.35 5,425 359,785
0.92 AMICUS THERAPEUT B19FQ48 10.43 22,526 359,437
0.92 MADRIGAL PHARMAC BD59BS7 216.05 1,085 358,624
0.91 KYMERA THERAPEUT BMPRZV5 36.30 6,371 353,809
0.91 AGIOS PHARMACEUT BCBVTX1 34.58 6,683 353,550
0.90 VERA THERAPEUTIC BL55460 43.50 5,281 351,447
0.89 IOVANCE BIOTHERA BF0DMK7 12.88 17,647 347,729
0.89 ROCKET PHARMACEU BDFKQ07 22.77 9,941 346,296
0.89 ALKERMES PLC B3P6D26 23.86 9,472 345,754
0.87 CATALYST PHARMAC B1G7Q03 15.02 14,707 337,947
0.87 DENALI THERAPEUT BD2B4V0 16.81 13,140 337,923
0.85 RECURSION PHAR-A BM9FJ13 8.79 24,760 332,962
0.85 ARDELYX INC BN89V40 6.79 31,883 331,195
0.84 INTELLIA THERAPE BYZM6C2 23.27 9,245 329,123
0.84 ARCUTIS BIOTHERA BKX9VD3 8.60 24,849 326,936
0.84 APELLIS PHARMACE BYTQ6X1 47.49 4,496 326,650
0.83 BIOCRYST PHARM 2100362 4.48 47,427 325,056
0.81 INHIBRX INC BK1MBC3 34.01 6,102 317,493
0.81 KEROS THERAPEUTI BM7V485 57.10 3,611 315,441
0.81 MIRUM PHARMACEUT BJDX8Y8 25.60 8,045 315,080
0.80 ARCELLX INC BPCJ1Q2 53.29 3,830 312,248
0.79 PROTHENA CORP PL B91XRN2 22.04 9,168 309,130
0.79 ACADIA PHARMACEU 2713317 17.08 11,820 308,859
0.78 ARROWHEAD PHARMA BYQBFJ8 24.13 8,283 305,773
0.76 KURA ONCOLOGY IN BYZD465 20.59 9,404 296,226
0.76 CRISPR THERAPEUT BDHF4K6 55.07 3,511 295,802
0.75 ALTIMMUNE INC BFY7DC4 7.19 26,666 293,320
0.75 MORPHIC HOLDING BK8M4J4 28.71 6,671 293,008
0.75 BIOHAVEN LTD BPLZ7S5 39.90 4,779 291,719
0.74 VERACYTE INC BFTWZY0 20.19 9,322 287,939
0.72 PROTAGONIST THER BDCBCD8 25.54 7,227 282,380
0.71 VIRIDIAN THERAPE BMDH2B6 14.58 12,354 275,562
0.69 AKERO THERAPEUTI BK7Y2V9 19.71 8,886 267,946
0.68 BIOMEA FUSION IN BNKF6N0 11.93 14,453 263,787
0.66 BEAM THERAPEUTIC BK6L288 22.72 7,382 256,588
0.66 DECIPHERA PHARMA BZ1LFB2 25.38 6,593 255,994
0.64 XENCOR INC BGCYWN8 23.63 6,930 250,525
0.64 MACROGENICS INC BFDV8K0 15.22 10,656 248,121
0.64 C4 THERAPEUTICS BKX9NQ0 6.43 25,188 247,776
0.62 ARCUS BIOSCIENCE BDZT9Y9 15.50 10,262 243,343
0.62 SOLENO THERAPEUT BL6JK96 49.23 3,207 241,537
0.62 SCHOLAR ROCK HOL BFZQ0L8 15.10 10,446 241,314
0.61 SAGE THERAPEUTIC BP4GNK9 13.11 11,856 237,700
0.61 AVIDITY BIOSCIEN BMWHPY1 25.58 6,072 237,622
0.61 COGENT BIOSCIENC BLR6XK8 7.29 21,296 237,509
0.57 SANA BIOTECHNOLO BMFJJ97 9.78 14,983 224,178
0.57 MYRIAD GENETICS 2614153 19.22 7,529 221,384
0.54 ADMA BIOLOGICS I B9NSBM2 6.74 20,613 212,547
0.54 EDITAS MEDICINE BZ8FPH3 5.62 24,348 209,341
0.53 CABALETTA BIO IN BK5MWR1 12.60 10,708 206,411
0.51 AVID BIOSERVICES BFMZ4W7 8.20 15,879 199,201
0.50 REPLIMUNE GROUP BDDVW37 6.56 19,399 194,687
0.49 ARCTURUS THERAPE BKC9SX3 26.52 4,731 191,947
0.49 4D MOLECULAR THE BKLXFX5 26.38 4,700 189,683
0.48 89BIO INC BK1K484 8.86 13,957 189,182
0.48 VIR BIOTECHNOLOG BK4PZ38 9.18 13,273 186,409
0.43 TRAVERE THERAPEU BLFGJD5 6.16 17,983 169,472
0.41 APOGEE THERAPEUT BM9HHL5 52.20 1,998 159,559
0.40 DAY ONE BIOPHARM BLB0YH0 17.57 5,838 156,924
0.40 CAREDX INC BP3YM74 9.27 11,021 156,299
0.39 ZENTALIS PHARMAC BMQ5T49 11.11 9,004 153,040
0.39 RELAY THERAPEUTI BN2R582 7.08 14,021 151,868
0.38 MANNKIND CORP BF081J4 4.38 22,119 148,216
0.35 REGENXBIO INC BZ0G875 16.64 5,434 138,334
0.35 FATE THERAPEUTIC BCZS820 4.10 22,045 138,277
0.35 DISC MEDICINE IN BMGJZJ8 29.00 3,108 137,890
0.35 OLEMA PHARMACEUT BMZ4LN0 10.07 8,904 137,173
0.32 KINIKSA PHARMA-A BD0MGM0 19.38 4,256 126,186
0.32 NURIX THERAPEUTI BMVLGP2 12.73 6,388 124,408
0.32 CULLINAN THERAPE BM90J52 27.58 2,932 123,712
0.31 VERVE THERAPEUTI BNKGXX2 6.15 13,039 122,680
0.31 SUMMIT THERAPEUT BMTVQS7 4.06 19,647 122,033
0.30 ANAVEX LIFE SCIE BYTYP72 3.76 20,241 116,433
0.28 ANAPTYSBIO INC BDRW1L7 26.34 2,740 110,413
0.28 ALLOGENE THERAPE BFZNYB7 2.97 23,739 107,863
0.26 MIMEDX GROUP INC B1Z3TW5 7.50 8,709 99,927
0.23 CARIBOU BIOSCIEN BNYJR68 3.64 16,358 91,093
0.20 TANGO THERAPEUTI BP2P6L0 7.59 6,647 77,183
0.17 ALECTOR INC BJ4LDC4 5.34 8,327 68,028
0.17 ASTRIA THERAPEUT BMYRFN8 9.35 4,729 67,645
0.15 MERSANA THERAPEU BF3NP05 3.36 11,131 57,217
0.13 ORIC PHARMACEUTI BKVDFF7 9.52 3,358 48,907
0.13 ARS PHARMACEUTIC BMCR7V2 9.46 3,371 48,787
0.12 VOYAGER THERAPEU BY7RB53 8.53 3,602 47,005
0.12 CARGO THERAPEUTI BQHN2F2 20.96 1,438 46,111
0.07 SCILEX HOLDING C BLKFRT9 0.85 21,910 28,438
0.05 AVITA MEDICAL IN BMX0JN6 8.72 1,559 20,798
Holdings are subject to change.

Sector Breakdown As of 3 May 2024

Sector Weight (%)
Health Care 99.8
Other/Cash 0.2

Country Breakdown As of 3 May 2024

Country Weight (%)
United States 97.4
Ireland 1.7
Switzerland 0.8
Other/Cash 0.1

Research

Investing in Pharma: The Drug Lifecycle

Read More

Charting Disruption: Medical Breakthroughs

Read More

AI Applications in Healthcare: From Drug Discovery to Patient Care

Read More

Documents

FAQs

  • What is biotechnology?

    Biotechnology includes companies primarily engaged in the research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering. It includes companies specialising in protein-based therapeutics to treat human diseases. It excludes companies manufacturing products using biotechnology but without a healthcare application. Biotechnology is a sub-industry of the healthcare sector.

  • How does biotechnology differ from healthcare?

    Biotechnology is a sub-industry within the Healthcare sector.

    The Healthcare sector refers to all those industries involved in providing goods and services to manage the health needs of individuals and populations. There are two main groupings within the healthcare sector according to the Global Industry Classification Standards (GICS) including:

    Healthcare equipment and services

    Pharmaceuticals, biotechnology, and Life Sciences.

  • How are companies in CURE weighted?

    Companies in CURE are equally weighted (subject to liquidity constraints), meaning each holding makes up the same portion of the portfolio at each quarterly rebalance and therefore contributes equally to overall performance.

    The choice of an equal weighting scheme provides investors exposure to the overall sector and allows all stocks to contribute equally to returns. Large-cap stocks do not dominate as they do where holdings are weighted by market capitalisation.

  • Why use CURE for biotechnology exposure?

    While biotechnology can be a lucrative space, it can also be high risk. The drug development process is very lengthy with high failure rates and it is an area that is sensitive to government policy. Using an ETF like CURE not only spreads the risk over many biotechnology companies but reduces the single stock risk further by using an equal weight method.

    CURE enables investors to access the growth in the U.S. biotechnology sector, without having to pick individual winners.

  • How can you use CURE in a portfolio?

    CURE may be used as a tool for expressing long-term strategic or short-term tactical views on the biotechnology sub-industry.

    CURE can also aid portfolio diversification via investment in a sector that is underrepresented in the Australian market.

Global X Management (AUS) Limited (“Global X”) (Australian Financial Services Licence Number 466778, ACN 150 433 828) is the product issuer. Offers of interests in any retail product will only be made in, or accompanied by, a Product Disclosure Statement (PDS). In respect of each retail product, Global X has prepared a target market determination (TMD). Each PDS and TMD is available at www.globalxetfs.com.au. The information on this website is general in nature only and does not take into account your personal objectives, financial situations or needs. Before acting on any information, you should consider the appropriateness of the information having regard to your objectives, financial situation or needs and consider seeking independent financial, legal, tax and other relevant advice having regard to your particular circumstances. Any investment decision should only be made after obtaining and considering the relevant PDS and TMD. Investments in any product issued by Global X are subject to investment risk, including possible delays in repayment and loss of income and principal invested. The value or return of an investment will fluctuate and an investor may lose some or all of their investment. Past performance is not a reliable indicator of future performance.

Back to Top
git